<DOC>
	<DOCNO>NCT00083824</DOCNO>
	<brief_summary>To clarify effect estrogen , without progestin , high density lipoprotein ( HDL ) postmenopausal woman .</brief_summary>
	<brief_title>Estrogen , HDL , Coronary Heart Disease Women</brief_title>
	<detailed_description>BACKGROUND : Coronary heart disease ( CHD ) lead cause death disability postmenopausal woman United States . Low plasma level high-density lipoprotein cholesterol ( HDL-C ) well-established risk factor CHD . Elevated plasma triglyceride ( TG ) level also risk factor CHD woman . HDL particles heterogeneous composition ( contain apo A-I , LpAI , apo A-I apo A-II , LpAIAII ) charge size ( preBeta1 , preBeta2 , alpha1-3 , preAlpha1-4 ) . Different HDL subpopulation different physiological function therefore may vary anti-atherogenic potential . Changes alpha1 HDL subpopulation predictor coronary disease progression men . Hormonal replacement therapy ( HRT ) increase plasma level HDL-C , adverse effect TG C-reactive protein ( CRP ) level . While observational study indicate protective role HRT CHD , recent intervention study show CHD protection use HRT . Our preliminary data indicate large inter-individual variability HDL subpopulation TG-rich lipoprotein remnant response HRT . The study use Estrogen Replacement Atherosclerosis ( ERA ) trial offer unique opportunity clarify effect estrogen without progestin HDL subpopulation TG-rich particle , effect genetic polymorphism response parameter HRT . In addition , ERA study allow test hypothesis HRT may benefit postmenopausal woman experience large increase HDL subpopulation ( regardless overall effect HDL cholesterol ) , without significant change TG level . In addition , look TG remnant TG-rich lipoprotein , study enable dissection beneficial adverse effect HRT . The ERA population consist 309 postmenopausal woman establish CHD participate randomize , placebo control , double-blind study effect placebo ( n-105 ) , estrogen ( n=100 ) , estrogen plus progestin ( n=104 ) progression coronary atherosclerosis , assess quantitative coronary angiography . The trial show difference coronary atherosclerosis progression across treatment group mean follow-up 3.2 year . DESIGN NARRATIVE : The study clarify effect estrogen , without progestin , HDL subpopulation lipoprotein remnant . It also examine impact change HDL subpopulation lipoprotein remnant HRT progression coronary atherosclerosis . These study conduct participant Estrogen Replacement Atherosclerosis ( ERA ) trial , randomize , placebo-controlled study HRT progression atherosclerosis postmenopausal woman CHD ( n=309 ) , baseline follow-up angiographic measurement coronary artery diameter obtain . The following HDL parameter measure : preBeta1 , preBeta2 , alpha1-3 , preAlpha1-4 HDL subpopulation 2dGE , LpAI LpAIAII plasma apo C-III HDL total plasma immuno-electrophoresis , lipoprotein remnant immunoseparation method , polymorphisms gene locus involve HDL metabolism ( lipoprotein lipase , hepatic lipase , cholesteryl ester transfer protein , scavenger receptor B1 , ATPA1 receptor ) . Hypotheses test : 1 ) HDL parameter lipoprotein remnant significantly associate severity CHD baseline ; 2 ) HRT-related change parameter predict coronary atherosclerosis progression ERA participant .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>Inclusion criterion : age &gt; 55 year without natural menses least 5 year serum FSH level &gt; 40 IU/L without natural menses least 1 bilateral oophorectomy document coronary artery disease Exclusion criterion : history breast endometrial carcinoma history deepvein thrombosis pulmonary embolism previous plan coronary bypass gallstone fast TG level &gt; 400 mg/dl uncontrolled diabetes uncontrolled hypertension serum creatinine &gt; 2 mg/dl &gt; 70 % stenosis leave main coronary artery .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>